TRIANA Bio is headquartered in Lexington, Massachusetts and focused on building a molecular glue discovery platform to inactivate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by high-resolution structural insights, stateof-the-art AI and computational tools, and bespoke chemical libraries. 

TRIANA’s target first and highly mechanistic approach to molecular glue discovery is focused on inducing or enhancing the degradation of high-profile cancer targets.